GMT Capital Corp Raises Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

GMT Capital Corp grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 140.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 508,800 shares of the specialty pharmaceutical company's stock after acquiring an additional 296,800 shares during the quarter. Jazz Pharmaceuticals comprises approximately 3.1% of GMT Capital Corp's holdings, making the stock its 14th largest holding. GMT Capital Corp owned 0.84% of Jazz Pharmaceuticals worth $62,659,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after buying an additional 507,234 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Jazz Pharmaceuticals by 2.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 38,184 shares of the specialty pharmaceutical company's stock worth $4,703,000 after acquiring an additional 1,041 shares during the last quarter. Quantessence Capital LLC purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $290,000. Diadema Partners LP bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $1,813,000. Finally, Hsbc Holdings PLC boosted its holdings in shares of Jazz Pharmaceuticals by 26.7% in the 4th quarter. Hsbc Holdings PLC now owns 2,871 shares of the specialty pharmaceutical company's stock worth $354,000 after purchasing an additional 605 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,023,305 over the last ninety days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Up 1.1 %

Jazz Pharmaceuticals stock traded up $1.27 during midday trading on Monday, hitting $112.07. 361,383 shares of the company's stock were exchanged, compared to its average volume of 796,800. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market cap of $6.81 billion, a PE ratio of 15.79, a P/E/G ratio of 1.04 and a beta of 0.42. The firm has a 50-day moving average of $124.64 and a two-hundred day moving average of $122.41. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several recent research reports. Needham & Company LLC restated a "buy" rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, April 10th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Royal Bank of Canada dropped their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.